Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Brighton Jones LLC

Brighton Jones LLC cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 14.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,032 shares of the biopharmaceutical company’s stock after selling 177 shares during the period. Brighton Jones LLC’s holdings in Alnylam Pharmaceuticals were worth $336,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company’s stock worth $3,525,544,000 after purchasing an additional 323,206 shares during the period. Adage Capital Partners GP L.L.C. lifted its stake in Alnylam Pharmaceuticals by 203.2% during the first quarter. Adage Capital Partners GP L.L.C. now owns 282,184 shares of the biopharmaceutical company’s stock worth $76,195,000 after purchasing an additional 189,128 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Alnylam Pharmaceuticals by 5.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock worth $946,466,000 after purchasing an additional 185,783 shares in the last quarter. SCS Capital Management LLC purchased a new position in shares of Alnylam Pharmaceuticals during the first quarter worth $46,194,000. Finally, Orbis Allan Gray Ltd grew its stake in shares of Alnylam Pharmaceuticals by 11.0% in the first quarter. Orbis Allan Gray Ltd now owns 1,634,923 shares of the biopharmaceutical company’s stock valued at $441,462,000 after buying an additional 162,121 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Down 6.7%

ALNY stock opened at $449.56 on Friday. The company’s 50 day moving average price is $460.16 and its 200 day moving average price is $367.47. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The firm has a market capitalization of $58.93 billion, a price-to-earnings ratio of -182.01 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.45. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company had revenue of $1.25 billion during the quarter, compared to the consensus estimate of $943.37 million. During the same quarter in the previous year, the firm earned ($0.50) earnings per share. The firm’s quarterly revenue was up 149.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the business’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the completion of the transaction, the executive vice president owned 25,231 shares in the company, valued at approximately $11,405,673.55. The trade was a 8.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the completion of the transaction, the executive vice president directly owned 54,052 shares in the company, valued at $24,434,206.60. This trade represents a 6.60% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 98,144 shares of company stock worth $44,160,261. 1.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Needham & Company LLC increased their target price on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research note on Thursday, July 31st. HC Wainwright reiterated a “buy” rating and set a $570.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 10th. Citigroup increased their price target on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. Wells Fargo & Company lifted their price objective on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the company an “equal weight” rating in a report on Friday, August 1st. Finally, Canaccord Genuity Group increased their target price on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Twenty-three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $473.79.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.